Recent Updates
Recently added Catalysts
GH Positive Sentiment Score: 75/100

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

Thursday, April 30, 2026 1 min read
Key Takeaway: Guardant Health has entered a multi-year strategic collaboration with Nuvalent to advance the development of companion diagnostics and support the commercialization of targeted cancer therapies. This partnership aims to leverage the Guardant Infinity™ platform, which offers both tissue and liquid biopsy options, enhancing precision in oncology treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strategic collaboration enhances precision oncology efforts.
  • Utilization of Guardant Infinity™ platform for cancer therapies.
  • Potential commercialization of innovative cancer treatments.

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, to support the development and potential commercialization of Nuvalent’s oncology pipeline using the tissue and liquid offerings of the Guardant Infinity™ platf

Frequently Asked Questions

What is the purpose of the collaboration between Guardant Health and Nuvalent?

The collaboration aims to develop companion diagnostics and support the commercialization of targeted cancer therapies.

What platform will be used in the collaboration?

The collaboration will utilize the Guardant Infinity™ platform for its tissue and liquid biopsy offerings.

What type of company is Nuvalent?

Nuvalent is a clinical-stage biopharmaceutical company focused on targeted therapies for cancer.

Where is Guardant Health located?

Guardant Health is based in Palo Alto, California.

Tags: GH Viatris Investor Conferences Healthcare Guardant Health Nuvalent precision oncology cancer therapies Guardant Infinity
Last updated: Apr 30, 2026